These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 31606237)

  • 1. Genetics and ESKD Disparities in African Americans.
    Umeukeje EM; Young BA
    Am J Kidney Dis; 2019 Dec; 74(6):811-821. PubMed ID: 31606237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease.
    Tzur S; Rosset S; Skorecki K; Wasser WG
    Nephrol Dial Transplant; 2012 Apr; 27(4):1498-505. PubMed ID: 22357707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions.
    Young BA; Blacksher E; Cavanaugh KL; Freedman BI; Fullerton SM; Kopp JB; Umeukeje EM; West KM; Wilson JG; Burke W;
    Am J Nephrol; 2019; 50(4):303-311. PubMed ID: 31480040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coding variants in nephrin (NPHS1) and susceptibility to nephropathy in African Americans.
    Bonomo JA; Ng MC; Palmer ND; Keaton JM; Larsen CP; Hicks PJ; ; Langefeld CD; Freedman BI; Bowden DW
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1434-40. PubMed ID: 24948143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.
    Hawkins GA; Friedman DJ; Lu L; McWilliams DR; Chou JW; Sajuthi S; Divers J; Parekh RS; Li M; Genovese G; Pollack MR; Hicks PJ; Bowden DW; Ma L; Freedman BI; Langefeld CD
    Am J Nephrol; 2015; 42(2):99-106. PubMed ID: 26343748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of coding variants identified from exome sequencing resources for association with diabetic and non-diabetic nephropathy in African Americans.
    Bailey JNC; Palmer ND; Ng MCY; Bonomo JA; Hicks PJ; Hester JM; Langefeld CD; Freedman BI; Bowden DW
    Hum Genet; 2014 Jun; 133(6):769-779. PubMed ID: 24385048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.
    Langefeld CD; Comeau ME; Ng MCY; Guan M; Dimitrov L; Mudgal P; Spainhour MH; Julian BA; Edberg JC; Croker JA; Divers J; Hicks PJ; Bowden DW; Chan GC; Ma L; Palmer ND; Kimberly RP; Freedman BI
    Kidney Int; 2018 Sep; 94(3):599-607. PubMed ID: 29885931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current State and Future Trends to Optimize the Care of African Americans with End-Stage Renal Disease.
    Harding K; Mersha TB; Webb FA; Vassalotti JA; Nicholas SB
    Am J Nephrol; 2017; 46(2):156-164. PubMed ID: 28787724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOL1 Nephropathy: From Genetics to Clinical Applications.
    Friedman DJ; Pollak MR
    Clin J Am Soc Nephrol; 2021 Feb; 16(2):294-303. PubMed ID: 32616495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-gene interactions in APOL1-associated nephropathy.
    Divers J; Palmer ND; Lu L; Langefeld CD; Rocco MV; Hicks PJ; Murea M; Ma L; Bowden DW; Freedman BI
    Nephrol Dial Transplant; 2014 Mar; 29(3):587-94. PubMed ID: 24157943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1.
    Lertdumrongluk P; Streja E; Rhee CM; Moradi H; Chang Y; Reddy U; Tantisattamo E; Kalantar-Zadeh K; Kopp JB
    Cardiorenal Med; 2019; 9(4):212-221. PubMed ID: 30995638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement factor H gene associations with end-stage kidney disease in African Americans.
    Bonomo JA; Palmer ND; Hicks PJ; Lea JP; Okusa MD; Langefeld CD; Bowden DW; Freedman BI
    Nephrol Dial Transplant; 2014 Jul; 29(7):1409-14. PubMed ID: 24586071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ras responsive transcription factor RREB1 is a novel candidate gene for type 2 diabetes associated end-stage kidney disease.
    Bonomo JA; Guan M; Ng MC; Palmer ND; Hicks PJ; Keaton JM; Lea JP; Langefeld CD; Freedman BI; Bowden DW
    Hum Mol Genet; 2014 Dec; 23(24):6441-7. PubMed ID: 25027322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sickle cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans.
    Hicks PJ; Langefeld CD; Lu L; Bleyer AJ; Divers J; Nachman PH; Derebail VK; Bowden DW; Freedman BI
    Kidney Int; 2011 Dec; 80(12):1339-43. PubMed ID: 21849968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. African American living-kidney donors should be screened for APOL1 risk alleles.
    Cohen DM; Mittalhenkle A; Scott DL; Young CJ; Norman DJ
    Transplantation; 2011 Oct; 92(7):722-5. PubMed ID: 21878839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target organ damage in African American hypertension: role of APOL1.
    Freedman BI; Murea M
    Curr Hypertens Rep; 2012 Feb; 14(1):21-8. PubMed ID: 22068337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOL1 Nephropathy Risk Alleles and Mortality in African American Adults: A Cohort Study.
    Gutiérrez OM; Irvin MR; Zakai NA; Naik RP; Chaudhary NS; Estrella MM; Limou S; Judd SE; Cushman M; Kopp JB; Winkler CA
    Am J Kidney Dis; 2020 Jan; 75(1):54-60. PubMed ID: 31563468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.
    Ma L; Langefeld CD; Comeau ME; Bonomo JA; Rocco MV; Burkart JM; Divers J; Palmer ND; Hicks PJ; Bowden DW; Lea JP; Krisher JO; Clay MJ; Freedman BI
    Kidney Int; 2016 Aug; 90(2):389-395. PubMed ID: 27157696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.
    Tzur S; Rosset S; Shemer R; Yudkovsky G; Selig S; Tarekegn A; Bekele E; Bradman N; Wasser WG; Behar DM; Skorecki K
    Hum Genet; 2010 Sep; 128(3):345-50. PubMed ID: 20635188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.
    Anyaegbu EI; Shaw AS; Hruska KA; Jain S
    Pediatr Nephrol; 2015 Jun; 30(6):983-9. PubMed ID: 25530085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.